Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas.
OBJECTIVE
The aim of the present study was to elucidate whether only local, or also systemic immunomodulatory effects may be induced by intravesical BCG therapy of superficial urinary bladder cancer.


METHODS
A total of 37 patients with stages Ta to T1b superficial transitional cell bladder carcinomas received 6 weekly BCG instillations after transurethral resection of the tumor. In a first group of 19 patients blood was taken before each BCG instillation and 6 weeks after the last one. In a second group of 18 patients blood and urine was taken before and 2, 6, and 24 hours after each BCG instillation. In the mitogen-stimulated whole blood cell cultures and in the urine samples the levels of the cytokines IL-1beta, IL-2, IL-10, TNF-alpha and IFN-gamma were determined by enzymoimmunological tests. Additionally, in all plasma and urine samples the levels of TNF-p75-receptor (TNF-p75-R) were measured.


RESULTS
Comparison of ex vivo leukocyte cytokine production in the blood cell cultures of the patients of group I revealed no significant change in the levels of the cytokines. In contrast, TNF-p75-R plasma levels increased significantly during the experimental time of 12 weeks (p < or =0.01). In the blood cell cultures of the group II patients a different daytime variation of cytokine production was seen, compared to the 19 healthy controls. After BCG instillation the normal peak cytokine production in the evening was suppressed. A significant rise in plasma TNF-p-75-R levels was measured 24 hours after BCG instillation (p < or =0.05). In the urine of these patients significantly higher levels of all measured cytokines and TNF-p75-R were observed 6 to 24 hours after the instillation.


CONCLUSIONS
The results suggest that besides the well known local immune activation, BCG instillation also leads to a modulation of peripheral immune mechanisms.
Elsässer-Beile
U
U
Department of Urology, University of Freiburg, Germany.
Gutzeit
O
O
Bauer
S
S
Katzenwadel
A
A
Schultze-Seemann
W
W
Wetterauer
U
U
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000368:Aged; D015703:Antigens, CD / Q000097:blood* / Q000187:drug effects; D001500:BCG Vaccine / Q000494:pharmacology*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D016207:Cytokines / Q000096:biosynthesis* / Q000187:drug effects; D005260:Female; D006801:Humans; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood* / Q000187:drug effects; D047889:Receptors, Tumor Necrosis Factor, Type II; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D001500:BCG Vaccine; D016207:Cytokines; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II